Scynexis has performed terribly during 2022 due to continued disappointment in earnings and sales ramp. New labels, including black-boxed warnings, could further hamper the slow commercial adoption of ...

Mycovia Pharmaceuticals, making its official debut as a company developing therapies in women's health and dermatology, today announced the initiation of two Phase 3 clinical trials called VIOLET to ...

Please provide your email address to receive an email when new articles are posted on . A single dose of an investigational fungal vaccine, NDV-3A, was safe and reduced episodes of recurrent ...

DURHAM, N.C.--(BUSINESS WIRE)--Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company, today announced the publication of its phase 3 ultraVIOLET study evaluating the ...

DURHAM, N.C.--(BUSINESS WIRE)--Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by ...

The drug, oteseconazole, is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis in females who are infertile or postmenopausal. The FDA recently approved the ...

The CANDLE study met its primary endpoint, with 65.4% of patients with recurrent vulvovaginal candidiasis (RVCC) who received monthly single-day ibrexafungerp treatment achieving clinical success with ...

Presentations to include topline findings from VIOLET Phase 3 extension study and first analysis of VIVJOA in RVVC patients with diabetes DURHAM, N.C.--(BUSINESS WIRE)--Mycovia Pharmaceuticals, Inc. ( ...

DURHAM – “The future of biopharma is in females,” says Mycovia Pharmaceuticals’ chief executive officer, Patrick Jordan. This week, Jordan represented his Durham company at the BIO Digital panel, ...

Vulvovaginal candidiasis is a common infection that causes vaginal and vulvar irritation and itchiness, as well as discharge. Most women will experience vulvovaginal candidiasis (VVC) during their ...

- NDA supported by positive data from VIOLET and ultraVIOLET Phase 3 clinical trials evaluating oteseconazole in more than 870 women in 11 countries - - Oteseconazole’s Qualified Infectious Disease ...